Quick Answer
CRESCENT BIOPHARMA, INC. reported Diluted EPS of $0.59 per share (loss) for fiscal year 2024.
CRESCENT BIOPHARMA, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$0.59 | -1.7% |
| 2023 | -$0.58 | +34.8% |
| 2022 | -$0.89 | +27.6% |
| 2021 | -$1.23 | -9.8% |
| 2020 | -$1.12 | +16.4% |
| 2019 | -$1.34 | -123.3% |
| 2014 | -$0.60 | +93.2% |
| 2013 | -$8.87 | -2787.9% |
| 2012 | $0.33 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | -$0.15 | -7.1% | +6.3% |
| June 30, 2024 | -$0.16 | -23.1% | -300.0% |
| March 31, 2024 | -$0.04 | +76.5% | +71.4% |
| September 30, 2023 | -$0.14 | +12.5% | -7.7% |
| June 30, 2023 | -$0.13 | +48.0% | +23.5% |
| March 31, 2023 | -$0.17 | +39.3% | -6.3% |
| September 30, 2022 | -$0.16 | +52.9% | +36.0% |
| June 30, 2022 | -$0.25 | +10.7% | +10.7% |
- CRESCENT BIOPHARMA, INC. showed a decrease of -1.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2012–2024 period, CRESCENT BIOPHARMA, INC.’s diluted eps has declined by 278.8% (from $0.33 per share to $0.59 per share (loss)).
- The most recent figure is from CRESCENT BIOPHARMA, INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on February 13, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: